Insmed (INSM) stock
Last close $141.33 on 2026-11-20 (-2.17%) · Sector: Healthcare
Insmed is a biopharmaceutical company, meaning it researches and develops medicines. It focuses on serious and rare diseases and makes money by selling those medicines to patients and healthcare providers.
Insmed's sales are growing fast, with trailing twelve-month revenue of $1.52 billion, but it still loses money on each share. Over the past year the stock fell 28.9%, while the S&P 500 rose 4.7%, so it has lagged the broader market. The stock trades 27.2% above its 50-day average and 15.3% above its 200-day average, and it is 33.6% below its 52-week high. Insiders sold $17.8 million of stock over the last 90 days and bought none, and the stock has often moved sharply after earnings reports.
Key numbers
- Market cap: $30.9B
- Revenue (last 12 months): $1.52B
- Revenue growth: +245.5%
- Gross margin: 84.2%
- Operating margin: -36.8%
- P/S: 20.3
- Debt to equity: 0.74
- Current ratio: 2.85
Quality score
Overall 51/100 · growth 100 · profitability 0 · financial health 53 · value None
Performance and risk
1-year return -28.9% vs S&P 500 +4.7% · volatility 66.5% (S&P 500 14.3%) · largest drop -56.5% · beta 0.33
Stock move the day after earnings
- 2026-02-19: +6.5%
- 2026-05-07: -23.4%
- 2026-08-06: +33.9%
- 2026-10-29: +15.1%
Insider trades (12 months)
Bought $0.0M · sold $148.4M
INSM stock research · INSM options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.